Abstract

Lupus erythematosus is an autoimmune disease that may manifest in a variety of organs and tissues including the skin, kidney, brain, heart and lung. Many patients present with cutaneous lupus, where disease is often limited to the skin, but are at risk for developing systemic lupus. The objective of our present study is to perform a systematic review of studies that investigated patient cohorts and populations for the occurrence of cutaneous lupus progressing to systemic lupus. Inclusion criteria required that studies present longitudinal data of patients with limited cutaneous lupus erythematosus who were followed for development of systemic lupus erythematosus. Studies were excluded if patients had concurrent diagnosis of SLE, or if they failed to present longitudinal data. Medline and Embase were searched for English language studies using the Ovid platform. A total of 25 adult studies were identified, as well as 8 pediatric studies. The rate of cutaneous to systemic lupus progression ranged between 0% to 42% in the adult studies and 0% to 31% in the pediatric groups. The variability in these rates were due to differences in patient populations, study design, criteria used to diagnose systemic lupus, and follow-up time. Common risk factors associated with systemic lupus erythematosus development including having positive anti-nuclear antibodies, hematologic abnormalities, and higher number of lupus classification criteria at baseline. This study emphasizes the importance for providers to routinely monitor for systemic lupus in patients with cutaneous lupus.

Highlights

  • Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease with a wide range of clinical presentations

  • As early as 1872, Moritz Kaposi identified a characteristic subset of patients with discoid lupus erythematosus (DLE) and found that while they may present with limited cutaneous disease, some may progress to systemic involvement [1]

  • Several classification criteria, including the American Rheumatism Association (ARA) criteria, American College of Rheumatology (ACR) criteria, Systemic Lupus International Collaborating Clinics (SLICC) criteria, and the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) criteria, have been developed to help clinicians monitor for the progression of CLE to systemic lupus erythematosus (SLE) [2–5]

Read more

Summary

Introduction

Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease with a wide range of clinical presentations. As early as 1872, Moritz Kaposi identified a characteristic subset of patients with DLE and found that while they may present with limited cutaneous disease, some may progress to systemic involvement [1]. Several classification criteria, including the American Rheumatism Association (ARA) criteria, American College of Rheumatology (ACR) criteria, Systemic Lupus International Collaborating Clinics (SLICC) criteria, and the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) criteria, have been developed to help clinicians monitor for the progression of CLE to systemic lupus erythematosus (SLE) [2–5]. Current standard of care involves checking CLE patients for systemic disease on presentation as well as interval assessments for the development of SLE [6, 7]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.